Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Testosterone Cypionate | Testosterone Propionate | |
|---|---|---|
| Category | Hormones | Hormones |
| Standard Dose | Research indicates 100-200 mg administered via intramuscular or subcutaneous injection every 7-14 days for testosterone replacement therapy. | Research indicates 25-50 mg administered every other day or 50-100 mg every 2-3 days via intramuscular or subcutaneous injection. |
| Timing | Inject on a consistent schedule. Twice-weekly dosing (e.g., Monday/Thursday) reduces peak-trough fluctuations. Morning injection preferred for alignment with circadian testosterone rhythm. | Every-other-day or daily injection required due to short half-life. Rotate injection sites to minimize tissue irritation. |
| Cycle Duration | Ongoing for TRT. If discontinuing, taper and implement PCT protocol. Testicular function suppression occurs within 2-4 weeks of initiation. | Short cycles (4-8 weeks) or as bridge therapy. Not typically used for long-term TRT due to injection frequency burden. |
| Evidence Level | strong_human | strong_human |
Testosterone cypionate is an esterified prodrug of testosterone that undergoes hydrolysis in vivo to release free testosterone. It binds the androgen receptor (AR), activating genomic pathways via AR nuclear translocation and transcription of anabolic genes including IGF-1, satellite cell proliferation, and nitrogen retention. Additionally, testosterone exerts non-genomic effects through membrane-associated AR signaling, modulating calcium influx and MAPK/ERK pathways. Aromatization to estradiol via CYP19A1 (aromatase) maintains bone density and lipid profiles.
Research indicates 100-200 mg administered via intramuscular or subcutaneous injection every 7-14 days for testosterone replacement therapy.
Inject on a consistent schedule. Twice-weekly dosing (e.g., Monday/Thursday) reduces peak-trough fluctuations. Morning injection preferred for alignment with circadian testosterone rhythm.
Ongoing for TRT. If discontinuing, taper and implement PCT protocol. Testicular function suppression occurs within 2-4 weeks of initiation.
Testosterone propionate is a short-acting esterified testosterone with a propionic acid ester, resulting in a half-life of approximately 0.8-1.5 days. Rapid hydrolysis by serum esterases produces a sharp testosterone spike followed by quick clearance. It activates the same androgen receptor-mediated genomic and non-genomic pathways as longer esters, but the pharmacokinetic profile demands frequent dosing. The short duration makes it useful for rapid onset situations and fine-tuned dose titration.
Research indicates 25-50 mg administered every other day or 50-100 mg every 2-3 days via intramuscular or subcutaneous injection.
Every-other-day or daily injection required due to short half-life. Rotate injection sites to minimize tissue irritation.
Short cycles (4-8 weeks) or as bridge therapy. Not typically used for long-term TRT due to injection frequency burden.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →